DBPR112, a novel small-molecule anticancer drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)

The Investigational New Drug (IND) application of …

Continue reading

Share Button

The novel smallmolecule anticancer drug candidate licensed to SynCore Biotechnology has been approved for the Phase II clinical trial by TFDA and US FDA

NHRI licensed “the novel small-molecule anticancer…

Continue reading

Share Button

The National Health Research Institutes (NHRI) and Molecular Targeting Technologies Inc. co-published the results of the cooperation on new anti-cancer therapeutics at the American Association for Cancer Research (AACR) meeting 2015

The National Health Research Institutes (NHRI) and…

Continue reading

Share Button

The novel anti-diabetic drug candidate DBPR108 developed in relays by IBPR with the collaborator received the approval to implement Phase I clinical trial from China Food and Drug Administration (CFDA).

IBPR has implemented the project, pre-clinical and…

Continue reading

Share Button